Summary : VivoPower International PLC (NASDAQ: VVPR) (“VivoPower,” the “Company”) is pleased to announce that its wholly-owned subsidiary in Australia, Kenshaw Electrical…
Global Market
-
-
Covid DrugsGlobal Market
Moderna eyes COVID booster by August, not clear yet if Omicron-specific needed
by adminby adminSummary : A study in monkeys pitting the current Moderna Inc (MRNA.O) COVID-19 booster against an Omicron-specific booster showed no significant differences…
-
Global MarketPharma Science & Research
Rovi seals 10-year Moderna deal extension to manufacture mRNA drugs
by adminby adminSummary : Spain’s Rovi (ROVI.MC) has agreed a 10-year extension to its deal with Moderna (MRNA.O) to manufacture future drugs developed with…
-
IndiaMankind Pharma
Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy’s Laboratories
by adminby adminSummary : Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy’s Laboratories to acquire two brands — Combihale and Daffy. While Combihale…
-
AstraZenecaIndia
Glenmark inks pact to commercialise AstraZeneca’s asthma drug in Colombian market
by adminby adminSummary : Glenmark Pharmaceuticals on Monday said its subsidiary has inked a pact to commercialise AstraZeneca’s asthma drug Pulmicort Respules in the…
-
India
Macleods Pharma files papers for IPO, likely to be one of the biggest in sector
by adminby adminSummary : The Rs 6,480-crore IPO of Gland Pharma, which was launched in November 2020, holds the record for the biggest ever…
-
Summary : Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes National Institute for Health…
-
Synopsis : Rare viral haemorrhagic disease similar to Ebola surface in the East of England. Two people in the UK have been…
-
Global MarketPharma Science & Research
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
by adminby adminSummary- Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)…
-
Global MarketPharma Science & Research
Lilly, Roche Push Back Against CMS Draft Guidance on Aduhelm
by adminby adminSummary The U.S. Centers for Medicare & Medicaid Services (CMS) just completed the open comment period for their draft national coverage decision…